Tafamidis (FX-1006)

Tafamidis is a potent kinetic stabilizer of transthyretin (TTR). Tafamidis binds selectively and with negative cooperativity (Kd values ?2nM and ?200nM) to the two normally unoccupied thyroxine-binding sites of the tetramer and kinetically stabilizes TTR. It prevents tetramer dissociation, the rate-limiting step in TTR misfolding and amyloidogenesis. Tafamadis also binds and stabilizes patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants. It is approved for the treatment of cardiomyopathy caused by transthyretin mediated amyloidosis in adults.

https://pubchem.ncbi.nlm.nih.gov/compound/11001318

Small volumes of Tafamidis biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS8400475 is a biochemical targeting Tafamidis.